Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

MeSH terms

• Adult
• Antineoplastic Agents, Immunological / therapeutic use
• Brentuximab Vedotin / therapeutic use*
• Combined Modality Therapy
• Drug Resistance, Neoplasm*
• Female
• Follow-Up Studies
• Hematopoietic Stem Cell Transplantation / methods*
• Humans
• Ki-1 Antigen / metabolism
• Lymphoma, Large-Cell, Anaplastic / metabolism
• Lymphoma, Large-Cell, Anaplastic / pathology
• Lymphoma, Large-Cell, Anaplastic / therapy*
• Lymphoma, Non-Hodgkin / metabolism
• Lymphoma, Non-Hodgkin / pathology
• Lymphoma, Non-Hodgkin / therapy*
• Lymphoma, T-Cell / metabolism
• Lymphoma, T-Cell / pathology
• Lymphoma, T-Cell / therapy*
• Male
• Middle Aged
• Neoplasm Recurrence, Local / metabolism
• Neoplasm Recurrence, Local / pathology
• Neoplasm Recurrence, Local / therapy*
• Prognosis
• Retrospective Studies
• Salvage Therapy
• Survival Rate
• Transplantation, Homologous
• Young Adult